News

Humanetics Secures Additional Funding to Advance Development of its Drug to Prevent Radiation Injury

Humanetics Corporation Advances Development of Novel Radiation Protection Drug with New Study Results

Humanetics Corporation Presents at the 2024 Department of Defense Scientific Meeting

Humanetics to Participate in the BIO Investor Forum in San Francisco

Uniformed Services University Awards Grant To Support Continued Collaboration with Humanetics to Develop Radiation Countermeasure

Humanetics to Present at the Biotechnology Innovation Organization (BIO) International Convention

Humanetics to Present at Investor and Partner Conferences

Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics

Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer

Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis

Humanetics Corporation Publishes Clinical Trial Results of BIO 300 in Patients with NSCLC

Humanetics Corporation Awarded Contract from Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury

BIO 300 Featured at the 2023 Military Health System Research Symposium

BIO 300 Enhances Radiotherapy Efficacy Against Lung Tumors in a NonClinical Model

Humanetics Announces Positive Results from Independent Data Monitoring Committee

BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury

Humanetics Corporation Presents at the MedInvest Oncology Investor Conference

Humanetics Corporation Publishes Results of Phase 1 Study of BIO 300 Oral Powder

Humanetics Corporation Presents at the 2022 Annual Radiation Research Society Meeting

FDA Clears BIO 300 Studies in Second Oncology Indication

Thomas F. Jasper Joins Board at Humanetics

Jake R. Nunn Joins Board at Humanetics

BIO 300 Pharmacokinetics Studies Published

US Department of Defense Awards $5.1 Million to Humanetics for Continued Development of Radiation Countermeasure

Humanetics Expands Clinical Sites for Long-Haul COVID-19 Trial

New Data Published Comparing BIO 300 with Neulasta

Humanetics Corporation Appoints Mr. Douglas W. Bryce to its Board of Advisors

Humanetics Corporation Adds Two New Board Members

Humanetics Corporation Completes Phase 1 Trial

Humanetics Corporation's BIO 300 Receives FDA Fast Track Designation

Humanetics Receives Funding to Study New Drug for Triple Negative Lung Cancer

Humanetics Receives Funding from Department of Defense for COVID-19 Studies

Humanetics Presents New Data at Radiation Research Society Meeting

Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Board of Directors

NIAID to Fund Clinical Trial of BIO 300 in COVID-19 Patients

Humanetics Invited for Oral Presentation at ASTRO

Dr. Colin Chinn, Former Joint Staff Surgeon, Joins Humanetics Medical Advisory Board

Humanetics Acquires Assets for Radioprotectant Drug

U.S DEPARTMENT OF DEFENSE AWARDS $6 MILLION TO HUMANETICS CORPORATION FOR ADVANCED DEVELOPMENT OF RADIOPROTECTANT

Humanetics to Present at the Annual Meeting of the American Society for Radiation Oncology

Humanetics Corporation Invited to Present Data on BIO 300 at Government Conference

Humanetics Presents Data on New Drug to Prevent Radiation Injury

Humanetics Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Exposure

Humanetics Awarded Federal Contract to Develop New Radiation Countermeasure to Protect the Lungs

Humanetics Corporation Presents at BIO CEO and Investor Conference

Humanetics Corporation Presents Data on Drug to Protect Cardiac Cells Against Toxicity from Space-like Radiation

Vice Admiral Matthew L. Nathan, M.D., Former Surgeon General of the U.S. Navy, Joins Humanetics' Medical Advisory Board

Humanetics Presents Data on BIO 300

Humanetics Receives Grant From NASA

Humanetics Received $3.8 Million Grant from Department of Defense

Humanetics Awarded Patent for BIO 300

Humanetics to Present at Department of Defense Scientific Meeting

Humanetics Awarded Patent to Mitigate Erectile Dysfunction Associated with Prostate Cancer Radiotherapy

Humanetics Received New Federal Grant to Continue Development of Radiation Countermeasure

Space Institute to Fund Testing of Radiation Protectants

Humanetics Corporation Granted FDA Clearance To Proceed With Cancer Treatment Study

New Grant Enables Humanetics Corporation to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients

Humanetics Corporation Enters Into Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Chemical Defense

Humanetics Corporation Granted Approval by the National Cancer Institute to Proceed with Cancer Treatment Study

Humanetics Corporation Awarded Patent Enabling Oral Administration of Powerful Radioprotectant

Humanetics Awarded Contract With National Cancer Institute